http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Baxter Launches PERCLOT Absorbable Hemostatic Powder
-
Baxter Declares Quarterly Dividend
-
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Baxter International Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – BAX
-
Baxter (BAX) Appoints William Ampofo to Its Board
-
Baxter Appoints William Ampofo to Its Board
-
Baxter Launches Progressa+ Next Gen ICU Bed to Help Address Complex Critical Care Needs
-
Baxter Publishes Annual Corporate Responsibility Report, Reinforcing Longstanding Commitment to Making a Meaningful Difference
-
Nuwellis Inc. Announces Pilot Agreement With DaVita Inc.
-
Baxter to Host Second-Quarter 2023 Financial Results Conference Call for Investors
-
Nuwellis to Participate in the Maxim Group Virtual Healthcare Conference
-
Nuwellis (NUWE) Announces Appointment of Mike McCormick to its Board of Directors
-
Nuwellis Announces the Appointment of Mike McCormick to its Board of Directors
-
Baxter to Present at Jefferies Healthcare Conference
-
Artivion (AORT) Announces FDA PMA Approval of PerClot and Transfer of PMA to Baxter (BAX)
-
Artivion Announces FDA PMA Approval of PerClot and Transfer of PMA to Baxter
-
Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Baxter (BAX) Announces CFO Transition, Maintains Outlook
-
Baxter Announces CFO Transition
-
Baxter (BAX) to Divest its BioPharma Solutions Business to Advent International and Warburg Pincus for $4.25 Billion
-
Baxter Signs Definitive Agreement to Divest its BioPharma Solutions Business to Advent International and Warburg Pincus for $4.25 Billion
-
Baxter (BAX) Appoints Chris Toth CEO of Proposed Kidney Care Spinoff
-
Baxter Names Chris Toth CEO of Proposed Kidney Care Spinoff
-
Baxter Declares Quarterly Dividend
-
Baxter Reports First-Quarter 2023 Results
-
Baxter to Present at BofA Securities 2023 Health Care Conference
-
Press release Biocartis Group NV: Biocartis appoints Roger Moody as new CEO
-
Baxter to Host First-Quarter 2023 Financial Results Conference Call for Investors
-
Baxter Launches Zosyn Premix in US
-
Baxter Showcases Surgical Innovations at AORN Global Surgical Conference and Expo 2023
-
Baxter to Host Annual Meeting of Stockholders in Virtual Format
-
Nuwellis to Present at the Oppenheimer 33rd Annual Healthcare Conference
-
Clinical Data Supports the Role of Ultrafiltration in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI)
-
Baxter Declares Quarterly Dividend
-
Baxter Reports Fourth-Quarter and Full-Year 2022 Results
-
Miromatrix Medical (MIRO), Baxter (BAX) Announce Collaborative Research Agreement Aiming to Advance Care for Patients with Acute Liver Failure
-
Miromatrix and Baxter Announce Collaborative Research Agreement Aiming to Advance Care for Patients with Acute Liver Failure
-
Miromatrix and Baxter Announce Collaborative Research Agreement Aiming to Advance Care for Patients with Acute Liver Failure
-
Miromatrix and Baxter Announce Collaborative Research Agreement Aiming to Advance Care for Patients with Acute Liver Failure
-
Baxter to Host Fourth-Quarter 2022 Financial Results Conference Call for Investors
-
Baxter (BAX) announces strategic actions, to spin off the company’s Renal Care and Acute Therapies global business units
-
Baxter Announces Strategic Actions to Enhance Operational Effectiveness, Accelerate Innovation for Patients and Drive Value for Shareholders
-
SeaStar Medical and Nuwellis Enter into a U.S. License and Distribution Agreement for SeaStar Medical’s Selective Cytopheretic Device (SCD) for Pediatric Acute Kidney Injury (AKI)
-
Baxter Named to Dow Jones Sustainability Indices for 23rd Consecutive Year
-
Baxter Introduces ExactaMix Pro, Next-Generation Automated Nutrition Compounder, at ASHP Meeting
-
Baxter to Present at the 5th Annual Evercore ISI HealthCONx Conference
-
Baxter Declares Quarterly Dividend
-
Baxter Highlights New Home Dialysis and HDx Therapy Data in 14 Clinical Presentations at Kidney Week 2022
-
Baxter Highlights New Home Dialysis and HDx Therapy Data in 14 Clinical Presentations at Kidney Week 2022
-
Baxter Reports Third-Quarter 2022 Results
-
The Baxter International Foundation Announces $3 Million in New Grants to Organizations Working to Advance Racial Justice

